IPS-3 Validation in 1012 cases with classical hodgkin lymphoma

Basit Öğe Kaydı
dc.authorid0000-0003-0882-0524en_US
dc.contributor.authorPaydaş, Semra
dc.contributor.authorLaçin, Şahin
dc.contributor.authorDoğan, Mutlu
dc.contributor.authorBarışta, İbrahim
dc.contributor.authorYıldız, Birol
dc.contributor.authorSeydaoğlu, Gülşah
dc.contributor.authorCivriz, Sinem
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorYağcı, Münci
dc.contributor.authorGürkan, Emel
dc.contributor.authorErçolak, Vehbi
dc.date.accessioned2022-06-22T13:05:56Z
dc.date.available2022-06-22T13:05:56Z
dc.date.issued2021en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalıen_US
dc.descriptionWOS:000628753200001
dc.descriptionPMID: 33556744
dc.description.abstractThe aim of this study is to validate the IPS-3 scoring system as a prognostic indicator in 1012 patients with advanced stage classical Hodgkin Lymphoma (cHL) treated by doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD). According to the IPS-3 scoring system only 3.5 % had high risk and 50.8 % had low risk disease disease and 45.8 % of the cases had intermediate risk disease. Each factors of IPS-7 and IPS-3 scoring systems (age, sex, stage hemoglobin, albumin, lymphocyte count and white cell count) were found to be significant for overall survival (OS) and progression free survival (PFS) according to univariate analyses. Two different multivariate Cox analyses were performed for OS and PFS including the IPS-3/ IPS-7 scoring system parameters. Among 7 risk factors of IPS scoring system, gender and albumin were not found as independent risk factors for both OS and PFS according to cox regression model. But all parameters such as age, stage and hemoglobin those included in IPS-3, were found to be independent significant risk factors for both models obtained for OS and PFS. The results of the study shows that the IPS-3 scoring system can be used as a prognostic indicator in ABVD treated patients in every day practice which is more easily calculate according to the IPS-7.en_US
dc.identifier.citationPaydaş, S., Laçin, Ş., Doğan, M., Barışta, İ., Yıldız, B., Seydaoğlu, G. ve diğerleri. (2021). IPS-3 Validation in 1012 cases with classical hodgkin lymphoma. Leukemia Research, (102). 1-5.en_US
dc.identifier.doi10.1016/j.leukres.2021.106519
dc.identifier.endpage5en_US
dc.identifier.issn0145-2126
dc.identifier.issn1873-5835
dc.identifier.pmid33556744
dc.identifier.scopus2-s2.0-85100422862
dc.identifier.scopusqualityQ3
dc.identifier.startpage1en_US
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0145212621000205?via%3Dihub
dc.identifier.urihttps://hdl.handle.net/11468/10059
dc.identifier.volume102en_US
dc.identifier.wosWOS:000628753200001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKaplan, Muhammed Ali
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science LTDen_US
dc.relation.ispartofLeukemia Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIPS-3en_US
dc.subjectHodgkin lymphomaen_US
dc.subjectValidationen_US
dc.subjectSurvivalen_US
dc.titleIPS-3 Validation in 1012 cases with classical hodgkin lymphomaen_US
dc.titleIPS-3 Validation in 1012 cases with classical hodgkin lymphoma
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
IPS-3 Validation in 1012 cases with classical hodgkin lymphoma.pdf
Boyut:
1.13 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu